Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revenues Up Despite Paroxetine Competition And Disappointing Ribavirin Launch, Par Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Par's second quarter revenues jumped despite disappointing revenues from the company's ribavirin generic and lower sales for paroxetine

You may also be interested in...



Andrx To Market Alphapharm Paxil Generic

Andrx will market Alphapharm's generic paroxetine (GlaxoSmithKline's Paxil) "shortly" under an agreement announced May 12

Three Rivers/Par, Sandoz Ribavirin ANDAs Approved By FDA; Companies Will Share Exclusivity

Three Rivers/Par launch Ribasphere at a 10% discount to Schering-Plough’s Rebetol. The generics are approved for use in combination with interferon alfa-2b for the treatment of hepatitis C.

Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal

A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel